GlycoErase™ XYLT2 Knockout Human Osteosarcoma Cell 143B (CAT#: GLJF-0525-JF237)

Description	The XYLT2 knockout 143B cell line, also involved in glycosaminoglycan biosynthesis, allows for exploration of the functional redundancy of XYLT1 and XYLT2 in bone sarcoma and their roles in cellular response.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:2~1:3
Cell Line	143B
Primary Disease	Osteosarcoma
Lineage	Bone

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	Bromodeoxyuridine & EMEM & FBS & Glutamine
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	XYLT2
Full Name	Xylosyltransferase 2
Alternative Name	PXYLT2, XT-II
Location	17q21.33
Gene ID	64132
Summary	Xylosyltransferase that initiates glycosaminoglycan chain biosynthesis; enzyme activity is increased in scleroderma patients and serves as a diagnostic marker.